Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: A survey among 1307 patients and their partners

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 162-171

  Teulings, Hansje Eva ^a,b   Overkamp, M ^a   Ceylan, E ^a   Nieuweboer Krobotova, L ^a,b   Bos, J D ^a   Nijsten, T ^c   Wolkerstorfer, A W ^a   Luiten, R M ^a   Van Der Veen, J P W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PSORALEN;

ADULT; AGE DISTRIBUTION; AGED; BASAL CELL CARCINOMA; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; NON MELANOMA SKIN CANCER; PATHOPHYSIOLOGY; PHOTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; RISK REDUCTION; SKIN CANCER; SKIN CARCINOMA; TREND STUDY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO;

AGE OF ONSET; AGED; ENVIRONMENTAL EXPOSURE; FEMALE; HEALTH BEHAVIOR; HUMANS; MALE; MELANOMA; MIDDLE AGED; NETHERLANDS; PHOTOTHERAPY; PREVALENCE; PROTECTIVE CLOTHING; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; SUNBURN; SUNSCREENING AGENTS; ULTRAVIOLET RAYS; VITILIGO;

EID: 84872835244     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12111     Document Type: Review

References (34)

1. Tæ̈eb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360:160-9.
2. Ogg GS, Rod Dunbar P, Romero P et al. High frequency of skinhoming melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188:1203-8.
3. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16:90-100.
4. Palermo B, Campanelli R, Garbelli S et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001; 117:326-32.
5. van den Boorn JG, Konijnenberg D, Dellemijn TA et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129:2220-32.
6. Jin Y, Birlea SA, Fain PR et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362:1686-97.
7. Bishop DT, Demenais F, Iles MM et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009; 41:920-5.
8. Boasberg PD, Hoon DS, Piro LD et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126:2658-63.
9. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709-18.
10. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100:8372-7.
11. Quaglino P, Marenco F, Osella-Abate S et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21:409-14.
12. Newton-Bishop JA, Chang YM, Elliott F et al. Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. Eur J Cancer 2011; 47:732-41.
13. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040-59.
14. Schallreuter KU, Tobin DJ, Panske A. Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed caucasian patients with vitiligo. Dermatology 2002; 204:194-201.
15. Hexsel CL, Eide MJ, Johnson CC et al. Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. J Am Acad Dermatol 2009; 60:929-33.
16. Diffey BL. Factors affecting the choice of a ceiling on the number of exposures with TL01 ultraviolet B phototherapy. Br J Dermatol 2003; 149:428-30.
17. Gawkrodger DJ, Ormerod AD, Shaw L et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159: 1051-76.
18. Branstrom R, Kasparian NA, Chang YM et al. Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev 2010; 19:2199-210.
19. Calanchini-Postizzi E, Frenk E. Long-term actinic damage in sunexposed vitiligo and normally pigmented skin. Dermatologica 1987; 174:266-71.
20. Hexsel CL, Bangert SD, Hebert AA, Lim HW. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labeling recommendations and combination sunscreen/insect repellent products. J Am Acad Dermatol 2008; 59:316-23.
21. Qureshi AA, Zhang M, Han J. Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of U.S. women. J Epidemiol 2011; 21:197-203.
22. Flohil SC, de Vries E, Neumann HA et al. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91:24-30.
23. Kiiski V, de Vries E, Flohil SC et al. Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010; 146:848-55.
24. 2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J 2009; 23:3790-807.
25. Schallreuter KU, Behrens-Williams S, Khaliq TP et al. Increased epidermal functioning wild-type p53 expression in vitiligo. Exp Dermatol 2003; 12:268-77.
26. Park KK, Murase JE, Koo J. Long-term prognosis of vitiligo patients on narrowband UVB phototherapy. J Am Acad Dermatol 2012; 66:326-7.
27. Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet Atreated patients. J Invest Dermatol 2005; 124:505-13.
28. Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66:553-62.
29. Stern RS. Malignant melanoma in patients treated for psoriasis with PUVA. Photodermatol Photoimmunol Photomed 1999; 15:37-8.
30. Halder RM, Battle EF, Smith EM. Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo. Arch Dermatol 1995; 131:734-5.
31. Harrist TJ, Pathak MA, Mosher DB, Fitzpatrick TB. Chronic cutaneous effects of long-term psoralen and ultraviolet radiation therapy in patients with vitiligo. Natl Cancer Inst Monogr 1984; 66:191-6.
32. Wildfang IL, Jacobsen FK, Thestrup-Pedersen K. PUVA treatment of vitiligo: a retrospective study of 59 patients. Acta Derm Venereol 1992; 72:305-6.
33. Holterhues C, Vries E, Louwman MW et al. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol 2010; 130:1807-12.
34. Hollestein LM, van den Akker SA, Nijsten T et al. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23:524-30.